loading
前日終値:
$0.7987
開ける:
$0.82
24時間の取引高:
179.69K
Relative Volume:
0.84
時価総額:
$41.49M
収益:
-
当期純損益:
$-131.52M
株価収益率:
-0.5274
EPS:
-1.78
ネットキャッシュフロー:
$-107.56M
1週間 パフォーマンス:
+24.78%
1か月 パフォーマンス:
+32.10%
6か月 パフォーマンス:
-46.66%
1年 パフォーマンス:
-75.62%
1日の値動き範囲:
Value
$0.82
$0.9387
1週間の範囲:
Value
$0.72
$0.9387
52週間の値動き範囲:
Value
$0.6101
$6.80

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name
名前
Prelude Therapeutics Inc
Name
セクター
Healthcare (1153)
Name
電話
(302) 467-1280
Name
住所
175 INNOVATION BOULEVARD, WILMINGTON
Name
職員
131
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
PRLD's Discussions on Twitter

PRLD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PRLD
Prelude Therapeutics Inc
0.9387 41.49M 0 -131.52M -107.56M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-09-19 アップグレード H.C. Wainwright Neutral → Buy
2024-06-20 ダウングレード Barclays Equal Weight → Underweight
2024-03-13 開始されました JMP Securities Mkt Outperform
2024-02-20 ダウングレード H.C. Wainwright Buy → Neutral
2023-12-19 ダウングレード Morgan Stanley Equal-Weight → Underweight
2022-11-21 ダウングレード BofA Securities Neutral → Underperform
2022-09-09 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-07-29 開始されました Jefferies Buy
2022-03-15 ダウングレード BofA Securities Buy → Neutral
2022-02-28 ダウングレード Barclays Overweight → Equal Weight
2021-10-08 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-07-27 アップグレード BofA Securities Neutral → Buy
2021-04-26 開始されました H.C. Wainwright Buy
2021-03-09 開始されました Barclays Overweight
2020-11-20 ダウングレード BofA Securities Buy → Neutral
2020-10-20 開始されました BofA Securities Buy
2020-10-20 開始されました Goldman Neutral
2020-10-20 開始されました Morgan Stanley Equal-Weight
すべてを表示

Prelude Therapeutics Inc (PRLD) 最新ニュース

pulisher
Apr 11, 2025

HC Wainwright Issues Positive Forecast for PRLD Earnings - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know - MSN

Apr 10, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo

Apr 02, 2025
pulisher
Apr 01, 2025

Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 29, 2025

Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo

Mar 29, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com India

Mar 28, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics stock surges on insider buying - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 26, 2025

PRLD stock touches 52-week low at $0.66 amid sharp annual decline - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ - openPR.com

Mar 25, 2025
pulisher
Mar 24, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock - Investing.com India

Mar 24, 2025
pulisher
Mar 22, 2025

Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MyChesCo

Mar 22, 2025
pulisher
Mar 19, 2025

Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 17, 2025

Prelude Therapeutics’ SWOT analysis: biotech stock faces mixed outlook amid clinical trials - Investing.com Australia

Mar 17, 2025
pulisher
Mar 16, 2025

NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial - MyChesCo

Mar 16, 2025
pulisher
Mar 14, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares - Investing.com

Mar 14, 2025
pulisher
Mar 13, 2025

Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements - MyChesCo

Mar 13, 2025
pulisher
Mar 12, 2025

Barclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD) - The Globe and Mail

Mar 12, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Purchases 154,826 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Increases Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - The AM Reporter

Mar 11, 2025
pulisher
Mar 11, 2025

Prelude Therapeutics Reports 2024 Financial Results - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77) - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Inc SEC 10-K Report - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Mar 10, 2025
pulisher
Mar 09, 2025

Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MyChesCo

Mar 09, 2025
pulisher
Mar 07, 2025

Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo

Mar 07, 2025
pulisher
Mar 06, 2025

Prelude Therapeutics to Present at Barclays Global Healthcare Conference - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MyChesCo

Mar 05, 2025
pulisher
Mar 05, 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

How Will Prelude's Cancer Pipeline Updates Impact Investors at Upcoming Barclays Conference? - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MyChesCo

Mar 05, 2025
pulisher
Mar 04, 2025

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Yahoo Finance

Mar 04, 2025
pulisher
Feb 28, 2025

Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN

Feb 28, 2025
pulisher
Feb 27, 2025

PRLD stock touches 52-week low at $0.79 amid market challenges - Investing.com

Feb 27, 2025

Prelude Therapeutics Inc (PRLD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
大文字化:     |  ボリューム (24 時間):